Although there is a rationale for use of concurrent bevacizumab and radiotherapy (inhibition of VEGF leads to transient normalization of tumour oxygenation, minimizing hypoxia and consequently inducing decreased radiation sensitivity [19]), few data are available concerning the late toxicity of this combination, with heterogeneous results. The gene discussed is VEGFA; the disease is neoplasm.